5. Response of treatment.
| Cases | Histology | Response | Distant metastasis | PFS (month) | OS (month) | Outcome |
| DL, dose level; ADC, adenocarcinoma; SCC, squamous cell carcinoma; ADSQ, adeno-squamous cell carcinoma; SD, stable disease; CR, complete response; PR, partial response; NE, not evaluable due to discontinuation of protocol treatment; N, none; PAN, para aortic lymph node; N/A, not applicable; DOD, died of disease; AWD, alive with disease; NED, no evidence of disease. | ||||||
| DL1-1 | ADC | SD | N | 5.6 | 21.6 | DOD |
| DL1-2 | SCC | CR | N | 7.0 | 16.3 | DOD |
| DL1-3 | SCC | CR | Virchow | 3.1 | 19.4 | AWD |
| DL2-1 | ADC | CR | N | N/A | 15.2 | DOD |
| DL2-2 | SCC | CR | PAN | 3.5 | 56.4 | AWD |
| DL2-3 | SCC | CR | Liver, PAN | 5.4 | 7.4 | DOD |
| DL2-4 | ADC | PR | N | N/A | 23.8 | NED |
| DL2-5 | SCC | CR | N | N/A | 28.0 | NED |
| DL3-1 | ADSQ | PR | Lung | N/A | 45.3 | NED |
| DL3-2 | SCC | SD | Virchow | 6.4 | 30.5 | AWD |
| DL3-3 | ADC | CR | N | N/A | 38.2 | NED |
| DL3-4 | EMC | SD | N | N/A | 7.8 | AWD |
| DL3-5 | SCC | CR | N | 7.0 | 28.2 | NED |
| DL3-6 | SCC | CR | N | N/A | 6.5 | NED |
| DL4-1 | SCC | PR | N | N/A | 29.8 | NED |
| DL4-2 | ADC | NE | N | 4.1 | 6.4 | DOD |
| DL4-3 | SCC | NE | PAN | 3.5 | 10.1 | AWD |